Neuroendocrine Tumors Therapeutics Market Size in the US was ~USD 1,530 million in 2023, is expected to grow by 2034, and estimates DelveInsight | Advanced Accelerator Applications (AAA)/Novartis, Ipsen Biopharmaceuticals, Novartis, Pfizer, Bausch Health

DelveInsight's "Neuroendocrine Tumor Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Neuroendocrine Tumor, historical and forecasted epidemiology as well as the Neuroendocrine Tumor market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover Key Insights into the Neuroendocrine Tumors Market with DelveInsight's In-Depth Report @ Neuroendocrine Tumors Market Size- https://www.delveinsight.com/sample-request/neuroendocrine-tumors-net-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Neuroendocrine Tumors Market Report
• In February 2025, Clarity Pharmaceuticals Ltd initiated a study to assess the performance of the imaging agent 64Cu-SARTATE in participants with known or suspected Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs). This study aims to explore a potential new method for diagnosing NETs.
• In February 2025, Novartis Pharmaceuticals launched a Phase IV, open-label, multi-center, single-arm study in China to evaluate the safety and efficacy of Everolimus (Afinitor) in adult patients with locally advanced, unresectable, or metastatic, well-differentiated progressive pancreatic neuroendocrine tumors (pNETs).
• In February 2025, Chimeric Therapeutics commenced a Phase 1/2 open-label study to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy, for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least one standard treatment regimen in the metastatic or locally advanced setting.
• The total number of incident cases of Neuroendocrine Tumors in the US was nearly 29,500 cases in 2023 and is projected to increase during the forecasted period.
• Non-functional/Asymptomatic/Unknown Neuroendocrine Tumors hold the largest contributors to the overall Neuroendocrine Tumors by functional status. The incident cases of Neuroendocrine Tumors in the United States were nearly 16,000 for Non-functional/Asymptomatic/Unknown Neuroendocrine Tumors and nearly 15,000 for Functional Neuroendocrine Tumors in 2023.
• Among EU4 and the UK, the highest number of cases for Neuroendocrine Tumors was found in the UK which was estimated to be nearly 30% of cases in EU4 and the UK in 2023.
• The establishment of comprehensive cancer registries and better reporting systems are now providing more accurate data on the incidence of Neuroendocrine Tumors. This is helping in understanding the true incidence of these tumors.
• Approximately 35-37% of patients had low-grade neuroendocrine neoplasms. This was followed by intermediate-grade neoplasms in 17-24% of patients, while only 6-7% of patients had high-grade disease. The grade status of the majority of patients remains unknown.
• The leading Neuroendocrine Tumor Companies such as Advanced Accelerator Applications (AAA)/Novartis, Ipsen Biopharmaceuticals, Novartis, Pfizer, Bausch Health and Ono Pharma, Merck, IITM Isotope Technologies Munich, Camurus, RayzeBio, Fundación de investigación HM, Radiomedix, Inc., Sinotau Pharmaceutical, Clarity Pharmaceuticals, ITM Solucin GmbH, Biotheus Inc., Aadi Bioscience, Inc., Novartis, TaiRx, Inc., Hutchmed, Perspective Therapeutics, Jiangsu HengRui Medicine, Nicholas Fidelman, MD, and others
• Promising Neuroendocrine Tumor Therapies such as LUTATHERA (lutetium Lu 177 dotatate), SOMATULINE DEPOT (lanreotide), AFINITOR (everolimus), (sunitinib malate), DEMSER Capsule (metyrosine), WELIREG (belzutifan/MK-6482), ITM-11, CAM2029, RYZ101, 177Lu-Dotatate, AlphaMedix, Lutetium[177Lu], 64Cu-SARTATE, 177Lu-edotreotide PRRT, PM8002, nab-sirolimus, [68Ga]Ga-DOTA-TATE, CVM-1118, Surufatinib, [212Pb]VMT-α-NET, 68Ga-DOTATOC, Pembrolizumab, and others

Stay ahead in the Neuroendocrine Tumors Therapeutics Market with DelveInsight's Strategic Report @ Neuroendocrine Tumors Market Outlook- https://www.delveinsight.com/sample-request/neuroendocrine-tumors-net-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Neuroendocrine Tumor Epidemiology Segmentation in the 7MM
• Total Prevalence of Neuroendocrine Tumor
• Prevalent Cases of Neuroendocrine Tumor by severity
• Gender-specific Prevalence of Neuroendocrine Tumor
• Diagnosed Cases of Episodic and Chronic Neuroendocrine Tumor

Download the report to understand which factors are driving Neuroendocrine Tumor epidemiology trends @ Neuroendocrine Tumor Epidemiological Insights- https://www.delveinsight.com/sample-request/neuroendocrine-tumors-net-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Neuroendocrine Tumors Marketed Drugs
• LUTATHERA (lutetium Lu 177 dotatate): Advanced Accelerator Applications (AAA)/Novartis
A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate (177Lu-DOTATATE; LUTATHERA), belongs to an emerging form of treatment called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumors with molecules carrying radioactive particles that bind to specific receptors expressed by the cancer. Lutetium Lu 177 dotatate may also be referred to as 177Lu-DOTA-Tyr3-octreotate.

• SOMATULINE DEPOT (lanreotide): Ipsen Biopharmaceuticals
SOMATULINE DEPOT is a somatostatin analog indicated for the treatment of adult patients with unresectable well or moderately differentiated, locally advanced, or metastatic GEP-Neuroendocrine Tumors to improve progression-free survival. The drug is also approved for the treatment of adults with carcinoid syndrome by reducing the frequency of short-acting somatostatin analog rescue therapy. The drug is administered subcutaneously.

Neuroendocrine Tumors Emerging Drugs
• ITM-11 (n.c.a. 177Lu-edotreotide): ITM Solucin GmbH
ITM-11 (177Lu-edotreotide) is known as an innovative targeted radionuclide therapy agent and is under investigation in the Phase III clinical trial COMPETE. ITM-11 shows a favorable safety profile and promising efficacy for the treatment of GEP-Neuroendocrine Tumors, for which only a few suitable and well-tolerated therapies are marketed. ITM-11 consists of two molecular components - firstly, Edotreotide (DOTATOC), an octreotide-derived somatostatin analog, and secondly, EndolucinBeta (no-carrier-added (n.c.a.) lutetium-177 chloride) a synthetic, low-energy beta-emitting therapeutic radioisotope.

• CAM2029: Camurus
CAM2029 is a long-acting octreotide subcutaneous depot under development for the treatment of three rare diseases: acromegaly, GEP-NET, and polycystic liver disease (PLD). CAM2029 is also ready to use and stored at room temperature. The randomized, active-controlled Pivotal Phase III SORENTO study evaluating the efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with GEP-Neuroendocrine Tumors progressed. Safety data collected to date was reviewed by a Data Monitoring Committee with no safety issues identified and the study recommended to continue without modifications.

Learn more about the FDA-approved drugs for Neuroendocrine Tumors @ Drugs for Neuroendocrine Tumors Treatment- https://www.delveinsight.com/sample-request/neuroendocrine-tumors-net-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Neuroendocrine Tumor Therapies and Companies
• LUTATHERA (lutetium Lu 177 dotatate): Advanced Accelerator Applications (AAA)/Novartis
• SOMATULINE DEPOT (lanreotide): Ipsen Biopharmaceuticals
• AFINITOR (everolimus): Novartis
• SUTENT
• (sunitinib malate): Pfizer
• DEMSER Capsule (metyrosine): Bausch Health and Ono Pharma
• WELIREG (belzutifan/MK-6482): Merck
• ITM-11: ITM Isotope Technologies Munich
• CAM2029: Camurus
• RYZ101: RayzeBio
• 177Lu-Dotatate: Fundación de investigación HM
• AlphaMedix: Radiomedix, Inc.
• Lutetium[177Lu]: Sinotau Pharmaceutical
• 64Cu-SARTATE: Clarity Pharmaceuticals
• 177Lu-edotreotide PRRT: ITM Solucin GmbH
• PM8002: Biotheus Inc.
• nab-sirolimus: Aadi Bioscience, Inc.
• [68Ga]Ga-DOTA-TATE: Novartis
• CVM-1118: TaiRx, Inc.
• Surufatinib: Hutchmed
• [212Pb]VMT-α-NET: Perspective Therapeutics
• Surufatinib: Hutchmed
• 68Ga-DOTATOC: Jiangsu HengRui Medicine
• RYZ101: RayzeBio, Inc.
• Pembrolizumab: Nicholas Fidelman, MD

Neuroendocrine Tumors Market Outlook
For many patients with Neuroendocrine Tumors, the administration of SSAs represents the current standard of care. In addition to an antisecretory effect, this therapy is also considered to have antiproliferative properties. In numerous studies, the time to tumor progression and overall survival were better than with placebo therapy. Newer therapeutic options include the administration of targeted therapies such as the mTOR antagonist everolimus. In contrast, cytotoxic chemotherapy is ineffective in GI-NET. Just recently, the so-called PRRT was established as a novel therapeutic option in Neuroendocrine Tumors patients' refractory to other treatments. Despite this progress, the prognosis of metastatic disease remains poor.

Discover more about Neuroendocrine Tumors Drugs in development @ Neuroendocrine Tumors Clinical Trials Assessment- https://www.delveinsight.com/sample-request/neuroendocrine-tumors-net-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Neuroendocrine Tumor Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Neuroendocrine Tumor Companies: Advanced Accelerator Applications (AAA)/Novartis, Ipsen Biopharmaceuticals, Novartis, Pfizer, Bausch Health and Ono Pharma, Merck, ITM Isotope Technologies Munich, Camurus, RayzeBio, Fundación de investigación HM, Radiomedix, Inc., Sinotau Pharmaceutical, Clarity Pharmaceuticals, ITM Solucin GmbH, Biotheus Inc., Aadi Bioscience, Inc., Novartis, TaiRx, Inc., Hutchmed, Perspective Therapeutics, Jiangsu HengRui Medicine, Nicholas Fidelman, MD, and others
• Neuroendocrine Tumor Therapies: LUTATHERA (lutetium Lu 177 dotatate), SOMATULINE DEPOT (lanreotide), AFINITOR (everolimus), (sunitinib malate), DEMSER Capsule (metyrosine), WELIREG (belzutifan/MK-6482), ITM-11, CAM2029, RYZ101, 177Lu-Dotatate, AlphaMedix, Lutetium[177Lu], 64Cu-SARTATE, 177Lu-edotreotide PRRT, PM8002, nab-sirolimus, [68Ga]Ga-DOTA-TATE, CVM-1118, Surufatinib, [212Pb]VMT-α-NET, 68Ga-DOTATOC, Pembrolizumab, and others
• Neuroendocrine Tumor Therapeutic Assessment: Neuroendocrine Tumor current marketed and Neuroendocrine Tumor emerging therapies
• Neuroendocrine Tumor Market Dynamics: Neuroendocrine Tumor market drivers and Neuroendocrine Tumor market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Neuroendocrine Tumor Unmet Needs, KOL's views, Analyst's views, Neuroendocrine Tumor Market Access and Reimbursement

Discover more about therapies set to grab major Neuroendocrine Tumor market share @ Neuroendocrine Tumor Treatment Landscape- https://www.delveinsight.com/sample-request/neuroendocrine-tumors-net-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Neuroendocrine Tumor Market Report Introduction
2. Executive Summary for Neuroendocrine Tumor
3. SWOT analysis of Neuroendocrine Tumor
4. Neuroendocrine Tumor Patient Share (%) Overview at a Glance
5. Neuroendocrine Tumor Market Overview at a Glance
6. Neuroendocrine Tumor Disease Background and Overview
7. Neuroendocrine Tumor Epidemiology and Patient Population
8. Country-Specific Patient Population of Neuroendocrine Tumor
9. Neuroendocrine Tumor Current Treatment and Medical Practices
10. Neuroendocrine Tumor Unmet Needs
11. Neuroendocrine Tumor Emerging Therapies
12. Neuroendocrine Tumor Market Outlook
13. Country-Wise Neuroendocrine Tumor Market Analysis (2020-2034)
14. Neuroendocrine Tumor Market Access and Reimbursement of Therapies
15. Neuroendocrine Tumor Market Drivers
16. Neuroendocrine Tumor Market Barriers
17. Neuroendocrine Tumor Appendix
18. Neuroendocrine Tumor Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

List of Top Selling Market Research Reports in 2025

Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Overactive bladder syndrome market- https://www.delveinsight.com/report-store/underactive-bladder-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Surgical sealant market - https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
Novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Ventral hernia market- https://www.delveinsight.com/report-store/hernia-repair-devices-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Trichotillomania market- https://www.delveinsight.com/sample-request/trichotillomania-ttm-market
Medical marijuana market- https://www.delveinsight.com/blog/medical-marijuana-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.